Logo image
Back
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs
Journal article   Open access   Peer reviewed

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs

Hannah Burton, Leora Boussi, David Nemirovsky, Andriy Derkach, Jenna Ciervo, Christopher Famulare, Kuo-Kai Chin, Yannis Valtis, Meira Yisraeli Salman, Kishan Patel, …
Cancer, v 131(16), e70024
15 Aug 2025
DOI: https://doi.org/10.1002/cncr.70024
PMID: 40772822
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1002/cncr.70024View
Published, Version of Record (VoR) Open

Abstract

Adult Aged Ambulatory Care - economics Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - economics Antimetabolites, Antineoplastic - therapeutic use Consolidation Chemotherapy - economics Consolidation Chemotherapy - methods Cytarabine - administration & dosage Cytarabine - adverse effects Cytarabine - economics Cytarabine - therapeutic use Female Health Care Costs Hospitalization - economics Hospitalization - statistics & numerical data Humans Induction Chemotherapy Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - economics Male Middle Aged Outpatients Retrospective Studies Young Adult
Administration of intensive induction chemotherapy followed by consolidation with postremission high- or intermediate-dose cytarabine (H/IDAC) remains a standard therapeutic approach in fit patients with nonadverse risk acute myeloid leukemia (AML). Historically, H/IDAC has been administered in the inpatient (IP) rather than outpatient (OP) setting given infection risk, transfusion and supportive care needs, and logistical challenges of OP treatment. However, the financial toxicity associated with IP chemotherapy hospitalization as well as risk of nosocomial infections and improvements in antimicrobial prophylaxis have highlighted the potential role for OP H/IDAC administration. Accordingly, an OP H/IDAC treatment program was developed at Memorial Sloan Kettering Cancer Center in 2014 using an ambulatory pump system. To investigate the benefits and risks of this approach compared with standard IP H/IDAC administration, a retrospective single-center cohort study was conducted of 198 adult patients with AML who received either IP (59) or OP (139) H/IDAC consolidation. In the OP-treated group, this approach safely reduced hospitalization days per cycle (median, 0.8 vs 7.5, p < .001) without leading to increased incidence of hospitalization for febrile neutropenia (incidence rate ratio, 1.07, p = .8) or higher rate of major treatment complications. Total cost per cycle was significantly lower for the OP-treated group (median, $14,244 compared to $36,688, p < .001). In the largest cohort study of adult AML patients receiving OP H/IDAC, OP treatment administration was feasible, led to decreased hospital days and cost savings, and did not impact relapse free or overall survival compared to IP administration.

Metrics

1 Record Views
1 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Logo image